Navigation Links
EntreMed Reports First Quarter 2011 Financial Results
Date:5/16/2011

enter Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including  the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid® resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in th
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Reports Third Quarter 2010 Financial Results
2. EntreMed Receives Notice of NASDAQ Compliance
3. EntreMed Secures $5.1 Million in Registered Direct Offering and Enters into Agreement for Rights to License ENMD-2076 in China
4. EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter
5. EntreMed Reports Second Quarter 2010 Financial Results
6. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. EntreMed Presents Initial Clinical Results for ENMD-2076
9. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
10. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... China , July 30, 2015 Tianyin ... a pharmaceutical company that specializes in the patented biopharmaceutical, ... pharmaceutical ingredients (API), provided updates regarding the notice it ... LLC (the "Exchange") indicating that the Company was below ... forth in Sections 134 and 1101 of the NYSE ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Robert Mazzacavallo has joined Veridiam as the company,s Chief ... of high-precision, fabricated assemblies and metal components, primarily serving ... aerospace and general industrial markets. , Before joining Veridiam, ... Camas, WA. At C-Tech, Bob worked closely with ...
... 3 Corgenix Medical Corporation (OTC Bulletin Board: CONX), ... will host a conference call on Thursday, November 12, ... financial and operating performance for the first quarter ended ... product development and marketing activities. , Corgenix invites all ...
Cached Medicine Technology:Veridiam Names Robert Mazzacavallo New CFO 2
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New York ... family members, medical professionals, and researchers, covering a variety of topics related to ... collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer ...
(Date:7/31/2015)... ... 2015 , ... Girl Scouts of Historic Georgia and Peach State Health Plan ... "Be a Friend First" program. Representatives from Peach State Health Plan presented a $10,000 ... Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying awareness. We ...
(Date:7/31/2015)... , ... July 31, 2015 , ... BioViva USA, Inc. ... way we treat aging diseases. , BioViva announces it has begun a fundraiser ... with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of the ...
(Date:7/31/2015)... Calgary, AB (PRWEB) , ... July 31, 2015 , ... ... changes. "When patients don't experience angina until a heart rate of 150 beats versus ... Fit Clinic in Calgary. "We are able to give life back to patients with ...
Breaking Medicine News(10 mins):Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... for majority of patients, survey found , WEDNESDAY, Aug. ... associated with neck problems, according to the results of ... aged 25 to 78, who had two types of ... (spine fusion). , Before the surgery, 86.4 percent of ...
... , NEW YORK, Aug. 12 ... of Ogilvy Healthworld North America, have been appointed Joint Worldwide CEOs ... Young. , , In making the announcement, Mr. ... they are also very complementary individuals. Their joint mandate is ...
... ... business culture and long history of technology innovation to enhance research, development and innovation ... Scottsdale, AZ ... management and security, today announced the expansion of its global operations with the opening ...
... Aug. 12 With obesity now the greatest threat to the health ... than ever. According to a new study in the August 2009 ... American Dietetic Association , portion and calorie-controlled meal replacements used in ... , , The st u ...
... SWARTZ CREEK, Mich., Aug. 12 Diplomat Specialty Pharmacy announced today they ... Inc.,s annual ranking of the fastest-growing private companies in America. ... is an amazing achievement, the additional details are even more resounding," stated Phil ... , , , Of the 43 ...
... , , DANA POINT, Calif., Aug. ... have selected Artefill, the first and only FDA-approved microsphere-enhanced collagen filler ... looking for a longer lasting dermal filler. Drs. Kofford have been ... success and effectiveness for the correction of wrinkles. , ...
Cached Medicine News:Health News:Surgery for Neck Pain May Also Relieve Headaches 2Health News:Joint Worldwide CEO's of Ogilvy Healthworld Named 2Health News:Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 2Health News:Lumension Expands Global Footprint and Strengthens Capabilities with the Opening of a New Development Office in Ireland 3Health News:New Published Diet Study Reveals Meal Replacements as Top Strategy for Weight Loss 2Health News:Diplomat Specialty Pharmacy Honored By Inc. Magazine As One Of The Nation's Fastest-Growing Companies 2Health News:Riviera Laser Studios Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Riviera Laser Studios Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3
... 3200 sets a benchmark of innovative, ... for WBC, RBC, PLT and Reticulocyte ... needs of today's laboratory. The instrument ... analysis, automated sample handling, comprehensive data ...
... Data Management System provides comprehensive program management ... and the Precision PCx. The QC Manager ... collect, analyze, and report quality control data ... essential laboratory tool for managing data and ...
... The CELL-DYN SMS consistently produces high-quality ... ensuring consistent blood films every time, eliminating ... with significantly high or low hematocrit values. ... autoloader mixes, identifies the sample, and aspirates ...
... The QuickVue In-Line Strep A Test allows for ... directly from patient throat swab specimens. , ,QuickVue ... and is the first strep A test waived ... rapid procedure allow testing to take place at ...
Medicine Products: